LifeSci Capital analyst Cory Jubinville, PhD has maintained their bullish stance on LQDA stock, giving a Buy rating today.
Cory Jubinville, PhD has given his Buy rating due to a combination of factors that highlight Liquidia Technologies’ promising outlook. The company is on the verge of launching its lead product, Yutrepia, following the anticipated expiration of Tyvaso’s exclusivity. This launch is expected to capitalize on favorable legal developments and strong clinical data from the ASCENT trial, which demonstrated significant improvements in patient outcomes.
Additionally, Liquidia’s ability to deliver higher doses of treprostinil with improved tolerability compared to existing treatments positions Yutrepia as a potentially superior option for patients. The recent Supreme Court decision not to hear an appeal related to a key patent further strengthens Liquidia’s position for a successful commercial launch. These factors, along with the updated price target, contribute to the positive Buy rating for Liquidia Technologies.
In another report released today, Needham also maintained a Buy rating on the stock with a $25.00 price target.
Questions or Comments about the article? Write to editor@tipranks.com